Knockdown of MPP8 suppresses cell proliferation via regulation of HOXA5 in non-small cell lung cancer cells.

Knockdown of MPP8 suppresses cell proliferation via regulation of HOXA5 in non-small cell lung cancer cells. Cell Mol Biol (Noisy-le-grand). 2018 Jan 31;64(1):27-31 Authors: Gao XY, Qiao YL, Zhang Y, Wang J, Shen X, Xu CW Abstract M-phase phosphoprotein 8 (MPP8) is reported to be closely implicated in cancer initiation and progression. In addition, the homeobox gene HOXA5 has been shown to play critical roles in hematopoiesis, embryogenesis, and tumorigenesis. Nevertheless, the functional relevance of MPP8 and it's relation with HOXA5 in non-small cell lung cancer (NSCLC) is unknown. Therefore, the present study aimed to detect the expression profile of MPP8 in NSCLC and further explore it's biological roles in lung cancer cells. Cell proliferation was measured by CCK-8 assay and EdU incorporation assay. Real-time PCR was applied to detect the mRNA expression of MPP8 and HOXA5. The protein levels of MPP8 and HOXA5 were evaluated by western blot. Our study found that the expression of MPP8 was significantly increased in the NSCLC tissue compared with the adjacent non-tumorous tissue. Compared with the human lung fibroblasts, the elevated gene expression of MPP8 was also detected in the human NSCLC cell lines including NCI-H23 and NCI-H1299. In addition, knockdown of MPP8 led to an obvious reduction in cell viability and DNA synthesis in NCI-H23 and NCI-H1299 cells. Furthermore, down-regulation of MPP8 resulted in elevated expression of HOXA5 in NSCLC cells...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Related Links:

During the production of this paper, an error appeared in the title. The title should be, “Immune Checkpoint Inhibition Combined With Intracranial Stereotactic Radiation Therapy in Non-Small Cell Lung Cancer: Is There an Increasing Rate of Radionecrosis or Not? In Regards to Schapira et al, Huppeling et al and Colaco et al.”
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Tags: Erratum Source Type: research
MicroRNA‑506‑3p reverses gefitinib resistance in non‑small cell lung cancer by targeting Yes‑associated protein 1. Mol Med Rep. 2018 Nov 29;: Authors: Zhu J, Tao L, Jin L Abstract Epidermal growth factor receptor‑tyrosine kinase inhibitors, such as gefitinib, have been found to be clinically effective in the treatment of patients with non‑small cell lung cancer (NSCLC). However, the therapeutic effect of gefitinib is often limited by the development of gefitinib resistance. MicroRNAs (miRNAs), a group of small non‑coding RNAs, have been demonstrated to be frequently dysregulated in human ...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
MicroRNA‑29a enhances cisplatin sensitivity in non‑small cell lung cancer through the regulation of REV3L. Mol Med Rep. 2018 Dec 04;: Authors: Chen X, Zhu H, Ye W, Cui Y, Chen M Abstract Cisplatin‑based chemotherapy may greatly enhance patient prognosis; however, chemotherapy resistance remains an obstacle to curing patients with non‑small cell lung cancer (NSCLC). The aim of the present study was to explore the microRNAs (miRs) that could regulate cisplatin sensitivity and provide a potential treatment method for cisplatin resistance in clinical. Results from the present study revealed that mi...
Source: Molecular Medicine Reports - Category: Molecular Biology Tags: Mol Med Rep Source Type: research
In this study, the expression level of FBXL3 in NSCLC tissues and cell lines was firstly examined and identified. Moreover, the relationship between FBXL3 and the overall survival rate of NSCLC patients was analyzed by Kaplan–Meier survival curve. Functionally, MTT, colony formation assay and transwell assays were performed to determine the role of FBXL3 in regulating NSCLC cell proliferation, migration and invasion. The proliferation and migration were suppressed by overexpression of FBXL3, indicating the potential tumor suppressive role of FBXL3 in NSCLC. In addition, the dual-luciferase reporter and RNA pull-down ...
Source: Pathology Research and Practice - Category: Pathology Source Type: research
This study investigated correlations of the clinical outcomes of oral metronomic vinorelbine (VNR) with VNR pharmacokinetics and MDR1 polymorphisms.MethodsEighty-two patients with metastatic non-small cell lung cancer (NSCLC) unfit for standard chemotherapy were treated with VNR at the oral doses of 20 –30 mg every other day or 50 mg three times a week. They had a performance status (PS) ≤ 3, were>  70-year-old and drug-naïve or cisplatin-pretreated. MDR1 2677G >  T and 3435C >  T polymorphisms were analysed and blood concentrations of VNR an...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionEGFR T790M mutation is a major mechanism of acquired resistance to afatinib. Osimertinib confers high response rates after afatinib failure inEGFR T790M-positive patients and its use in sequence potentially allows extended chemotherapy-free treatment.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
The long-term results from an analysis of two phase II studies confirmed the role of osimertinib in the treatment of T790M mutation –positive advanced non–small-cell lung cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Chunyan Wang, Enqi Liu, Wen Li, Jue Cui, Tongxiang Li
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 10 December 2018Source: PhytomedicineAuthor(s): Xuewei Wang, Zhengtang Liu, Xinbing Sui, Qibiao Wu, Jue Wang, Cong XuAbstractBackgroundElemene injection is an anticancer Chinese patent medicine that is widely used for the treatment of advanced lung cancer. Its active ingredients are β-, γ- and δ-elemene, which are extracted from Curcuma aromatica Salisb. (Curcuma wenyujin Y.H. Chen &C. Ling).PurposeTo evaluate the effects of Elemene injection as adjunctive treatment to platinum-based chemotherapy (PBC) in patients with stage III/IV non-small cell l...
Source: Phytomedicine - Category: Drugs & Pharmacology Source Type: research
Publication date: 10 December 2018Source: Cancer Cell, Volume 34, Issue 6Author(s): Pei-Chih Lee, Yueh-Fu Fang, Hirohito Yamaguchi, Wei-Jan Wang, Tse-Ching Chen, Xuan Hong, Baozhen Ke, Weiya Xia, Yongkun Wei, Zhengyu Zha, Yan Wang, Han-Pin Kuo, Chih-Wei Wang, Chih-Yen Tu, Chia-Hung Chen, Wei-Chien Huang, Shu-Fen Chiang, Lei Nie, Junwei Hou, Chun-Te ChenSummaryMultiple mechanisms of resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have been identified in EGFR-mutant non-small cell lung cancer (NSCLC); however, recurrent resistance to EGFR TKIs due to the heterogeneous mechanisms underl...
Source: Cancer Cell - Category: Cancer & Oncology Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Genetics | Lung Cancer | Molecular Biology | Non-Small Cell Lung Cancer | Study